Still, targeting-related research on some TF families is scarce, for example, within Activating enhancer-binding Protein 2 (AP-2); this is unexpected because the members of this family are known for their altered functionality in cancer and prognostic importance in oncological patients [20,21]. The gene discussed is TF; the disease is cancer.